CVKD: Prakiraan wutah bathi kanggo taun ngarep Cadrenal Therapeutics, Inc

Cadrenal Therapeutics - logo grafis emiten CVKD

The earnings per share growth model for next year is based on the digitalization of data collection during clinical trials, which reduces costs. The stability of research in the US is ensured by a neutral geopolitical climate. Meanwhile, 22.10 represents the current metric, highlighting the potential of Tecarfarin in treating thrombosis in dialysis patients to capture the anticoagulant market for Cadrenal Therapeutics (CVKD).

CVKD - Prakiraan wutah bathi resik saben saham ing taun ngarep Cadrenal Therapeutics Inc. ing rentang 28.04.2023 - 17.11.2026

Rincian analitis lan laporan data perusahaan Cadrenal Therapeutics, Inc. (CVKD)

Analisis umum perusahaan:CVKD, Cadrenal Therapeutics
Produk dadi cadrenal.com

To verify the credit quality of Cadrenal Therapeutics (CVKD), the analyst evaluates the company's ability to generate future cash flow. Business sustainability is based on the commercialization of Tecarfarin for dialysis patients, which directly impacts net income expectations. By analyzing the historical trend of the next year's EPS forecast, the investor can see the consolidated expert opinion on profit growth rates, allowing for the timely identification of risks regarding asset undervaluation or overheating.